P-076 The impact of heterogeneous disease distribution on MRD detection in patients with relapsed multiple myelomaLukas John, Niels Weinhold, Martin Grözinger et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0
P-011 Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/ refractory multiple myeloma are associated with pre-CAR-T bridging therapiesJan Frenking, Marc S. Raab, Joseph Kauer et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0
P-482 Dietary habits correlate with myeloma pathogenesis and treatment outcome in multiple myelomaLilli Sester, Marc S. Raab, Anna Katharina Gambihler et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0
P-151 Dietary Oleic Acid Influences the Myeloma Immune Microenvironment and Improves Clinical OutcomesLilli Sester, Marc‐Steffen Raab, Jan Frenking et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0